• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

    6/13/24 4:05:00 PM ET
    $PLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRX alert in real time by email

    SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Board of Directors.

    "Steve is a tremendous addition to our board, bringing extensive strategic leadership experience and a depth of financial expertise that will benefit Pliant's continued evolution as a late-stage clinical company," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. "Steve's broad financial experience will be highly complimentary to the strong science and business expertise on the board. We look forward to his insights."

    Mr. Krognes is a highly accomplished biopharmaceutical executive who brings over 30 years of financial and corporate strategy experience in leading and guiding life science companies across all stages of development. Most recently, and up until his retirement in 2022, Mr. Krognes served as Chief Financial Officer of Denali Therapeutics, a role he founded, contributing significantly to the company's strong financial position and growth. Prior to this, Mr. Krognes held the role of Chief Financial Officer at Genentech overseeing the integration of Genentech and Roche Holding AG in the U.S. and Genentech and InterMune. Prior to Genentech, Mr. Krognes served as Global Head of Mergers and Acquisitions at Roche. Early in his career, Mr. Krognes worked in the investment banking division of Goldman Sachs, served as a management consultant at McKinsey & Company and was a venture capitalist in Scandinavia.

    In addition to Pliant, Mr. Krognes currently serves on the boards of publicly listed Denali Therapeutics, Guardant Health and argenx, as well as privately held ClavystBio, based in Singapore. Mr. Krognes received an M.B A. from Harvard Business School and a B.S. in Economics from the Wharton School of the University of Pennsylvania.

    About Pliant Therapeutics, Inc.

    Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.

    For additional information, please visit: www.PliantRx.com. Follow us on social media: X, LinkedIn, Facebook and YouTube.

    Forward-Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those regarding the safety, tolerability, pharmacodynamics and therapeutic potential of bexotegrast; our plans for the future development of bexotegrast, PLN-101325 and PLN-101095; bexotegrast's potential to become a treatment for IPF and the potential future utilization of PET imaging technology to identify IPF therapies. Because such statements deal with future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned preclinical or clinical trials, the impact of current macroeconomic and marketplace conditions, including the effects of health epidemics and pandemics, such as COVID-19, on our business, operations, clinical supply and plans, our reliance on third parties for critical aspects of our development operations, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, our capital requirements and the need for additional financing, including the availability of additional term loans under our loan facility, and our ability to obtain and maintain intellectual property protection for our product candidates. These and additional risks are discussed in the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the period ended December 31, 2023, as updated in our Quarterly Report on Form 10-Q for the period ended March 31, 2024, each available on the SEC's website at www.sec.gov. Unless otherwise noted, Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    Investor and Media Contact:

    Christopher Keenan

    Vice President, Investor Relations and Corporate Communications

    Pliant Therapeutics, Inc.

    [email protected]



    Primary Logo

    Get the next $PLRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PLRX

    DatePrice TargetRatingAnalyst
    3/4/2025Buy → Hold
    Needham
    3/4/2025Neutral
    Cantor Fitzgerald
    3/3/2025Buy → Hold
    Stifel
    3/3/2025Outperform → Market Perform
    Leerink Partners
    2/10/2025Overweight → Neutral
    Analyst
    2/10/2025$43.00 → $4.00Buy → Hold
    Canaccord Genuity
    2/10/2025Outperform → Perform
    Oppenheimer
    2/10/2025$40.00 → $4.00Buy → Neutral
    Citigroup
    More analyst ratings

    $PLRX
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pliant Therapeutics Inc.

      SCHEDULE 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      5/15/25 4:39:50 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pliant Therapeutics Inc.

      SCHEDULE 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      5/14/25 10:45:26 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Pliant Therapeutics Inc.

      10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

      5/8/25 4:16:45 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Human Resource Officer Cheung Lily was granted 25,875 shares, increasing direct ownership by 105% to 50,425 units (SEC Form 4)

      4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

      1/27/25 6:14:06 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel & Corp. Sec'y Ouimette Mike was granted 35,000 shares, increasing direct ownership by 50% to 105,544 units (SEC Form 4)

      4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

      1/27/25 6:10:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Business Officer Hull Hans was granted 40,150 shares, increasing direct ownership by 19% to 251,708 units (SEC Form 4)

      4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

      1/27/25 6:07:17 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

      SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS from Multiple ILD SubtypesIn a featured oral presentation, Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics, discussed an evaluation of the antifibrotic activity of bexotegrast in fibrotic human precision-cut lung slices (PCLS) generated from non-id

      5/21/25 4:03:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2025 financial results. "During the first quarter and over recent weeks, our teams have been working diligently to close out the g

      5/8/25 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

      -  Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials -  Pliant will reduce its current workforce by approximately 45% -  Closing activities for BEACON-IPF trial ongoing; topline data expected in the second quarter of 2025 SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to extend the cash runway to support execution of late-stage clinical trials. The restructuring aims to minimize costs and preserve cash reserves as the Company awaits topline data from the BEACON-IPF Phase 2b/3 trial of be

      5/1/25 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

      Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r

      3/3/25 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Appoints Delphine Imbert, Ph.D. as Chief Technical Officer

      Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related acti

      1/22/25 8:00:00 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.

      11/7/24 4:05:00 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pliant Therapeutics downgraded by Needham

      Needham downgraded Pliant Therapeutics from Buy to Hold

      3/4/25 8:19:24 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Pliant Therapeutics

      Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral

      3/4/25 7:42:23 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics downgraded by Stifel

      Stifel downgraded Pliant Therapeutics from Buy to Hold

      3/3/25 3:36:54 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PLRX
    Financials

    Live finance-specific insights

    See more
    • SEC Form SC 13G filed by Pliant Therapeutics Inc.

      SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      11/14/24 9:00:58 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

      SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      11/14/24 5:05:23 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

      SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

      11/14/24 4:47:50 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

      SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take

      3/13/25 7:20:00 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

      Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced

      2/4/24 3:29:07 PM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

      Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f

      9/26/23 7:30:00 AM ET
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care